Grand Jean Capital Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-19,134
| Closed | -$9.95M | – | 44 |
|
|
2024
Q4 | $9.95M | Sell |
19,134
-5,878
| -24% | -$3.23M | 2.31% | 18 |
|
|
2024
Q3 | $15.5M | Buy |
25,012
+628
| +3% | +$372K | 3.46% | 12 |
|
|
2024
Q2 | $13.5M | Sell |
24,384
-766
| -3% | -$439K | 3.36% | 15 |
|
|
2024
Q1 | $14.6M | Sell |
25,150
-442
| -2% | -$248K | 3.86% | 13 |
|
|
2023
Q4 | $13.6M | Sell |
25,592
-8,118
| -24% | -$3.93M | 4.06% | 12 |
|
|
2023
Q3 | $18.8M | Buy |
33,710
+180
| +0.5% | +$95.9K | 5.84% | 4 |
|
|
2023
Q2 | $17.5M | Buy |
33,530
+5
| +0% | +$2.7K | 5.93% | 5 |
|
|
2023
Q1 | $19.3M | Buy |
33,525
+3,642
| +12% | +$2.05M | 7.44% | 4 |
|
|
2022
Q4 | $16.5M | Buy |
29,883
+1,503
| +5% | +$796K | 7.42% | 4 |
|
|
2022
Q3 | $14.4M | Buy |
28,380
+474
| +2% | +$265K | 6.38% | 5 |
|
|
2022
Q2 | $15.2M | Sell |
27,906
-6,210
| -18% | -$3.42M | 6.07% | 3 |
|
|
2022
Q1 | $20.2M | Sell |
34,116
-1,321
| -4% | -$759K | 5.53% | 3 |
|
|
2021
Q4 | $23.6M | Buy |
35,437
+1,573
| +5% | +$982K | 5.88% | 3 |
|
|
2021
Q3 | $19.3M | Buy |
33,864
+401
| +1% | +$220K | 4.89% | 3 |
|
|
2021
Q2 | $16.9M | Buy |
33,463
+418
| +1% | +$197K | 4.18% | 9 |
|
|
2021
Q1 | $15.1M | Sell |
33,045
-1,574
| -5% | -$751K | 3.99% | 12 |
|
|
2020
Q4 | $16.1M | Buy |
34,619
+136
| +0.4% | +$63.8K | 4.56% | 9 |
|
|
2020
Q3 | $15.2M | Sell |
34,483
-3
| -0% | -$1.24K | 5.84% | 4 |
|
|
2020
Q2 | $12.5M | Sell |
34,486
-117
| -0.3% | -$39.2K | 5.02% | 9 |
|
|
2020
Q1 | $9.81M | Sell |
34,603
-11,275
| -25% | -$3.56M | 5.37% | 8 |
|
|
2019
Q4 | $14.9M | Hold |
45,878
| – | – | 5.7% | 6 |
|
|
2019
Q3 | $13.4M | Sell |
45,878
-9,683
| -17% | -$2.77M | 5.62% | 6 |
|
|
2019
Q2 | $16.3M | Sell |
55,561
-10,105
| -15% | -$2.78M | 6.61% | 6 |
|
|
2019
Q1 | $18M | Sell |
65,666
-11,567
| -15% | -$2.88M | 7.32% | 3 |
|
|
2018
Q4 | $17.3M | Sell |
77,233
-9,487
| -11% | -$2.23M | 8.31% | 3 |
|
|
2018
Q3 | $21.2M | Sell |
86,720
-4,608
| -5% | -$1.06M | 7.39% | 3 |
|
|
2018
Q2 | $18.9M | Sell |
91,328
-1,657
| -2% | -$352K | 6.73% | 3 |
|
|
2018
Q1 | $19.2M | Sell |
92,985
-16,745
| -15% | -$3.51M | 7.27% | 2 |
|
|
2017
Q4 | $20.8M | Sell |
109,730
-1,148
| -1% | -$220K | 6.99% | 2 |
|
|
2017
Q3 | $21M | Sell |
110,878
-191
| -0.2% | -$34.6K | 7.53% | 2 |
|
|
2017
Q2 | $19.4M | Sell |
111,069
-855
| -0.8% | -$144K | 7.4% | 2 |
|
|
2017
Q1 | $17.2M | Buy |
111,924
+26,981
| +32% | +$4.12M | 6.28% | 6 |
|
|
2016
Q4 | $12M | Sell |
84,943
-1,766
| -2% | -$260K | 4.56% | 10 |
|
|
2016
Q3 | $13.8M | Sell |
86,709
-32,204
| -27% | -$4.96M | 5.89% | 6 |
|
|
2016
Q2 | $16.8M | Hold |
118,913
| – | – | 7.26% | 3 |
|
|
2016
Q1 | $16.8M | Sell |
118,913
-9,730
| -8% | -$1.3M | 7.15% | 3 |
|
|
2015
Q4 | $18.2M | Sell |
128,643
-763
| -0.6% | -$102K | 8.03% | 1 |
|
|
2015
Q3 | $15.8M | Buy |
+129,406
| New | +$16.9M | 7.17% | 3 |
|
Other funds holding TMO
Grand Jean Capital Management's TMO Position: Q1 2025 in Review
Grand Jean Capital Management sold out of Thermo Fisher Scientific (TMO) in Q1 2025, closing a stake of 19,134 shares — an estimated $9.95M sold.
Grand Jean Capital Management first reported a position in TMO in Q3 2015 and held it in 38 quarters. The position peaked at $23.6M in Q4 2021. 2,578 funds tracked by Wall St. Rank hold TMO as of Q1 2025.
- Grand Jean Capital Management reported no remaining Thermo Fisher Scientific position as of Q1 2025 after selling out during the quarter.
- Grand Jean Capital Management sold 19,134 Thermo Fisher Scientific shares in Q1 2025, an estimated $9.95M.
- Grand Jean Capital Management first reported a position in Thermo Fisher Scientific in Q3 2015 and held it in 38 quarters.
- Grand Jean Capital Management's Thermo Fisher Scientific position peaked at $23.6M in Q4 2021.
- 2,578 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2025.
Based on Grand Jean Capital Management's 13F filing for Q1 2025.